William D. Waddill sold $979k of PTGX
director at Protagonist Therapeutics, Inc. 12,000 shares at an average of $81.62, traded Oct 10, 2025, filed Oct 14, 2025.
Score components
- +15RoleDirector
- +25Trade size$979k at market
- +20Share of holdings soldSold 70% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-099252, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 10, 2025 | MOption exercise Common Stock10b5-1 | +12,000 | $6.98 | $84k | 17,130 | Oct 14, 2025 |
| Oct 10, 2025 | SOpen-market sale Common Stock10b5-1 | -4,000 | $69.25 | $277k | 13,130 | Oct 14, 2025 |
| Oct 10, 2025 | SOpen-market sale Common Stock10b5-1 | -8,000 | $87.81 | $702k | 5,130 | Oct 14, 2025 |
| Oct 10, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 0 | Oct 14, 2025 |
Related signals
Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $8.3M 58,629 shares | -50% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $18M 125,000 shares | -22% | |
| 57Moderate | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $2.6M 24,765 shares | -29% | |
| 45Moderate | Protagonist Therapeutics, Inc | Arturo Molina Md Chief Medical Officer | $1.6M 15,000 shares | -15% | |
| 55Moderate | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $5.5M 54,700 shares | -10% | |
| 57Moderate | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $3.8M 46,203 shares | -43% | |
| 45Moderate | Protagonist Therapeutics, Inc | Arturo Molina Md Chief Medical Officer | $1.9M 23,151 shares | -24% | |
| 50Moderate | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $4.1M 48,273 shares | -8% | |
| 58Moderate | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $708k 8,588 shares | -10% | |
| 52Moderate | Protagonist Therapeutics, Inc | Arturo Molina Md Chief Medical Officer | $785k 9,514 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.